Volume 26, Number 8—August 2020
Research
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Manish Patel
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
Table 4
Prevalence of immunosuppressive conditions by person age and sex for acute respiratory illness in the MarketScan database, United States, July 2012–August 2017
| Characteristic | All enrollees, person-years, no. (%)* | Immunosuppressive conditions† |
|
|---|---|---|---|
| Person-years (%) | Prevalence/100 person-years, % | ||
| Total |
115,113,322 (100) |
6,823,509 (100) |
5.9 |
| Age, y | |||
| <1–8 | 11,074,106 (10) | 160,137 (2) | 1.4 |
| 9–17 | 13,666,230 (12) | 474,703 (7) | 3.5 |
| 18–49 | 52,413,795 (46) | 2,580,737 (38) | 4.9 |
| 50–64 | 28,552,259 (25) | 2,470,817 (36) | 8. |
| >65 |
9,406,932 (8) |
1,137,115 (17) |
12.1 |
| Sex | |||
| M | 55,282,285 (48) | 2,597,852 (38) | 4.7 |
| F | 59,831,037 (52) | 4,225,657 (62) | 7.1 |
*Person-time was calculated by using the total months each enrollee spent in a health plan supplying data to MarketScan during the study period. During August 2012–July 2017, a total of 47.2 million unique enrollees were in our MarketScan analysis.
†See Figure 1. Denotes patients had International Classification of Diseases codes for either 3 immunosuppressive conditions OR 3 conditions + immunosuppressive pharmacologic treatment (chemotherapeutic agents or immune-modeling agents or systemic corticosteroids >14 d).
Page created: April 29, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.